Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study
Biodesix (Nasdaq: BDSX) announced new data presentation at CHEST 2024 Annual Meeting and launch of a complementary clinical study. The presentation will showcase the use of Nodify Lung® Nodule Risk Assessment in over 35,000 patients in real-world settings. Dr. Kathryn Long will present findings on reclassification rates for lung cancer risk, highlighting how the tests help clarify diagnostic plans.
Additionally, Biodesix introduced the CLARIFY study, a retrospective chart review of up to 4,000 patients, aimed at confirming the performance of Nodify CDT® and Nodify XL2® tests in diverse patient subgroups. This study will expand evidence supporting Nodify Lung testing's validation and utility.
CEO Scott Hutton emphasized the impact of Nodify Lung testing on lung nodule risk characterization over the past four years. The CHEST conference will also feature a presentation on patient impact and case studies by Drs. Sonali Sethi and D. Kyle Hogarth.